| Previous close | 111.60 |
| Open | 111.60 |
| Bid | 112.45 x 28400 |
| Ask | 112.55 x 2100 |
| Day's range | 111.55 - 112.65 |
| 52-week range | 86.03 - 123.90 |
| Volume | 328,078 |
| Avg. volume | 2,010,734 |
| Market cap | 93.05B |
| Beta | N/A |
| PE ratio (TTM) | 18.61 |
| EPS (TTM) | 6.05 |
| Earnings date | 27 Jul 2017 |
| Dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 120.58 |
- Reuters•2 days ago
Campaign group Avaaz calls on EU to block Bayer's Monsanto deal
Online campaigns group Avaaz has called on European Union antitrust regulators to block Bayer's purchase of Monsanto, saying it would hurt innovation and competition and push up prices. Avaaz said in a letter to European Competition Commissioner Margrethe Vestagerhad that more than one million people had signed its petition opposing the merger of the German and U.S. companies, which it said would have a major impact on farmers. "It would control more than one-fourth of the combined global market for seeds and pesticides and lock farmers ever tighter into a supply chain for products that threaten biodiversity and food security by creating dangerous, genetically modified and pesticide-addicted monocultures," Avaaz lawyer Nick Flynn said in the letter.
- EQS Group•5 days ago
MorphoSys Announces That Its Partner Bayer Reports On Phase 2 Study of Investigational Anetumab Ravtansine in Second-Line Mesothelioma (news with additional features)
DGAP-News: MorphoSys AG / Key word(s): Miscellaneous21.07.2017 / 18:05 The issuer is solely responsible for the content of this announcement.
- Bloomberg•5 days ago
Bayer Faces EU Test in Race to Close Monsanto Deal by Year-End
Bayer AG’s plan to ward off an in-depth European Union investigation into its $66 billion combination with Monsanto Co. faces a test at a meeting early next week that could jeopardize their goal of closing ...
